Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309214351
Category : Medical
Languages : en
Pages : 894
Get Book Here
Book Description
In 1900, for every 1,000 babies born in the United States, 100 would die before their first birthday, often due to infectious diseases. Today, vaccines exist for many viral and bacterial diseases. The National Childhood Vaccine Injury Act, passed in 1986, was intended to bolster vaccine research and development through the federal coordination of vaccine initiatives and to provide relief to vaccine manufacturers facing financial burdens. The legislation also intended to address concerns about the safety of vaccines by instituting a compensation program, setting up a passive surveillance system for vaccine adverse events, and by providing information to consumers. A key component of the legislation required the U.S. Department of Health and Human Services to collaborate with the Institute of Medicine to assess concerns about the safety of vaccines and potential adverse events, especially in children. Adverse Effects of Vaccines reviews the epidemiological, clinical, and biological evidence regarding adverse health events associated with specific vaccines covered by the National Vaccine Injury Compensation Program (VICP), including the varicella zoster vaccine, influenza vaccines, the hepatitis B vaccine, and the human papillomavirus vaccine, among others. For each possible adverse event, the report reviews peer-reviewed primary studies, summarizes their findings, and evaluates the epidemiological, clinical, and biological evidence. It finds that while no vaccine is 100 percent safe, very few adverse events are shown to be caused by vaccines. In addition, the evidence shows that vaccines do not cause several conditions. For example, the MMR vaccine is not associated with autism or childhood diabetes. Also, the DTaP vaccine is not associated with diabetes and the influenza vaccine given as a shot does not exacerbate asthma. Adverse Effects of Vaccines will be of special interest to the National Vaccine Program Office, the VICP, the Centers for Disease Control and Prevention, vaccine safety researchers and manufacturers, parents, caregivers, and health professionals in the private and public sectors.
Author: Leyi Wang
Publisher:
ISBN:
Category :
Languages : en
Pages :
Get Book Here
Book Description
Abstract: In this study, several strategies have been explored for the development of live attenuated and killed DIVA influenza vaccines. The NS1 protein of influenza A viruses, a virulence marker, is a good target to attenuate viruses in developing a live attenuated vaccine. Through passage in eggs, we found that several different NS1 truncation variants were generated from a parental non-stable virus strain, A/turkey/Oregon/71-delNS1 (H7N3). Based on the results from both in vitro and in vivo studies, naturally selected NS1 truncation variants are potentially live attenuated influenza vaccine candidates in poultry. With a large deletion in NS genes, those NS1 truncation variants have a low possibility to revert back to virulent viruses. We then checked feasibility of those NS1 truncation variants to be used for in ovo vaccination, and hatchability of vaccinated groups was significantly lower than that of PBS control group, indicating that NS1 truncation variants were not attenuated enough to be used for in ovo vaccination and there was a need for further attenuation. To improve hatchability of NS1 truncation variant vaccinated eggs, temperature sensitive (ts) mutation and HA substitution strategies were utilized. NS1 truncation variants containing ts mutations exhibited ts phenotype in vitro, but were not attenuated enough to improve hatchability of in ovo vaccination. We showed that HA substitution had different effect on hatchability of in ovo vaccination, and the hatchability of eggs inoculated with NS1 truncation variants of different HA subtypes was still significantly lower than PBS control group. Therefore, we explored a strategy of targeting non-conserved parts of non-coding regions (NCR) to attenuate NS1 truncation variant viruses. In vitro studies illustrated that even single nucleotide change in NCR of PA or PB1 segments could affect protein expression. In addition, it was found that mutations in NCR of PA segment alone or PA and PB1 combination affect virus replication. With more understanding of the role of NCR in virus replication cycle, we speculate targeting non-conserved parts of NCR to further attenuate NS1 truncation variants is feasible. Further study is needed to introduce those mutations involved in decreased virus replication into NS1 truncation variants for further attenuation. In the case of development of killed DIVA avian influenza vaccines, two strategies, NS1 protein and heterologous NA, were utilized to generate DIVA vaccines. In vivo study showed that both kinds of DIVA vaccines significantly reduced challenge virus shedding in the oviduct of breeder turkeys as well as trachea and cloaca of young and breeder turkeys compared to the non-vaccinated control group, which suggests proper vaccination could effectively prevent egg production drop and potential viral contamination of eggs in infected turkeys. In combination with DIVA serological tests, we expect the developed vaccines will be useful to control turkey H3N2 influenza.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309490359
Category : Medical
Languages : en
Pages : 231
Get Book Here
Book Description
In November 2018, an ad hoc planning committee at the National Academies of Sciences, Engineering, and Medicine planned two sister workshops held in Washington, DC, to examine the lessons from influenza pandemics and other major outbreaks, understand the extent to which the lessons have been learned, and discuss how they could be applied further to ensure that countries are sufficiently ready for future pandemics. This publication summarizes the presentations and discussions from both workshops.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309174988
Category : Medical
Languages : en
Pages : 472
Get Book Here
Book Description
Vaccines have made it possible to eradicate the scourge of smallpox, promise the same for polio, and have profoundly reduced the threat posed by other diseases such as whooping cough, measles, and meningitis. What is next? There are many pathogens, autoimmune diseases, and cancers that may be promising targets for vaccine research and development. This volume provides an analytic framework and quantitative model for evaluating disease conditions that can be applied by those setting priorities for vaccine development over the coming decades. The committee describes an approach for comparing potential new vaccines based on their impact on morbidity and mortality and on the costs of both health care and vaccine development. The book examines: Lessons to be learned from the polio experience. Scientific advances that set the stage for new vaccines. Factors that affect how vaccines are used in the population. Value judgments and ethical questions raised by comparison of health needs and benefits. The committee provides a way to compare different forms of illness and set vaccine priorities without assigning a monetary value to lives. Their recommendations will be important to anyone involved in science policy and public health planning: policymakers, regulators, health care providers, vaccine manufacturers, and researchers.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309095042
Category : Medical
Languages : en
Pages : 431
Get Book Here
Book Description
Public health officials and organizations around the world remain on high alert because of increasing concerns about the prospect of an influenza pandemic, which many experts believe to be inevitable. Moreover, recent problems with the availability and strain-specificity of vaccine for annual flu epidemics in some countries and the rise of pandemic strains of avian flu in disparate geographic regions have alarmed experts about the world's ability to prevent or contain a human pandemic. The workshop summary, The Threat of Pandemic Influenza: Are We Ready? addresses these urgent concerns. The report describes what steps the United States and other countries have taken thus far to prepare for the next outbreak of "killer flu." It also looks at gaps in readiness, including hospitals' inability to absorb a surge of patients and many nations' incapacity to monitor and detect flu outbreaks. The report points to the need for international agreements to share flu vaccine and antiviral stockpiles to ensure that the 88 percent of nations that cannot manufacture or stockpile these products have access to them. It chronicles the toll of the H5N1 strain of avian flu currently circulating among poultry in many parts of Asia, which now accounts for the culling of millions of birds and the death of at least 50 persons. And it compares the costs of preparations with the costs of illness and death that could arise during an outbreak.
Author:
Publisher:
ISBN: 9780309087810
Category :
Languages : en
Pages :
Get Book Here
Book Description
Author: Canada. Comité consultatif national de l'immunisation
Publisher:
ISBN: 9780660193922
Category : Immunization
Languages : en
Pages : 392
Get Book Here
Book Description
The seventh edition of the Canadian Immunization Guide was developed by the National Advisory Committee on Immunization (NACI), with the support ofthe Immunization and Respiratory Infections Division, Public Health Agency of Canada, to provide updated information and recommendations on the use of vaccines in Canada. The Public Health Agency of Canada conducted a survey in 2004, which confi rmed that the Canadian Immunization Guide is a very useful and reliable resource of information on immunization.
Author: Gina Kolata
Publisher: Farrar, Straus and Giroux
ISBN: 1429979356
Category : Social Science
Languages : en
Pages : 378
Get Book Here
Book Description
Veteran journalist Gina Kolata's Flu: The Story of the Great Influenza Pandemic of 1918 and the Search for the Virus That Caused It presents a fascinating look at true story of the world's deadliest disease. In 1918, the Great Flu Epidemic felled the young and healthy virtually overnight. An estimated forty million people died as the epidemic raged. Children were left orphaned and families were devastated. As many American soldiers were killed by the 1918 flu as were killed in battle during World War I. And no area of the globe was safe. Eskimos living in remote outposts in the frozen tundra were sickened and killed by the flu in such numbers that entire villages were wiped out. Scientists have recently rediscovered shards of the flu virus frozen in Alaska and preserved in scraps of tissue in a government warehouse. Gina Kolata, an acclaimed reporter for The New York Times, unravels the mystery of this lethal virus with the high drama of a great adventure story. Delving into the history of the flu and previous epidemics, detailing the science and the latest understanding of this mortal disease, Kolata addresses the prospects for a great epidemic recurring, and, most important, what can be done to prevent it.
Author: Marta L. DeDiego
Publisher: MDPI
ISBN: 3039288172
Category : Science
Languages : en
Pages : 130
Get Book Here
Book Description
The influenza virus poses a threat to human health and is responsible for global epidemics every year. In addition to seasonal infections, influenza can cause occasional pandemics of great consequence when novel viruses are introduced into humans. Despite the implementation of comprehensive vaccination programs, influenza viruses continue to pose an important and unpredictable global public health threat. They are one of the most significant causes of morbidity and mortality each year and have a significant economic impact. In recent years, research has been conducted to find alternative approaches to influenza vaccine development, including the generation of universal vaccines. Notably, significant progress in the field of influenza infection, transmission, and immunity have contributed to our understanding of influenza biology, and to expanding the technological approaches for the generation of more efficient strategies against influenza infections. Moreover, highly remarkable developments have been made in the implementation of new methodologies to evaluate the efficiency of vaccines and improve them for use on domestic animals such as poultry, horses, dogs or pigs. This enables us to decrease the exposure of humans to potentially pandemic viruses. The articles in this Special Issue will address the importance of influenza to human health and the advances in influenza research that have led to the development of better therapeutics and vaccination strategies.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309185548
Category : Medical
Languages : en
Pages : 397
Get Book Here
Book Description
Infectious diseases are a global hazard that puts every nation and every person at risk. The recent SARS outbreak is a prime example. Knowing neither geographic nor political borders, often arriving silently and lethally, microbial pathogens constitute a grave threat to the health of humans. Indeed, a majority of countries recently identified the spread of infectious disease as the greatest global problem they confront. Throughout history, humans have struggled to control both the causes and consequences of infectious diseases and we will continue to do so into the foreseeable future. Following up on a high-profile 1992 report from the Institute of Medicine, Microbial Threats to Health examines the current state of knowledge and policy pertaining to emerging and re-emerging infectious diseases from around the globe. It examines the spectrum of microbial threats, factors in disease emergence, and the ultimate capacity of the United States to meet the challenges posed by microbial threats to human health. From the impact of war or technology on disease emergence to the development of enhanced disease surveillance and vaccine strategies, Microbial Threats to Health contains valuable information for researchers, students, health care providers, policymakers, public health officials. and the interested public.
